Daily Cosmetic Research Analysis
Three studies advance cosmetic and dermatologic science from bench to bedside. A mechanistic paper shows that juglone and plumbagin irreversibly inhibit PTP1B in keratinocytes, enhancing EGFR phosphorylation. A plant-derived extract (Saxifraga stolonifera) suppresses melanogenesis via the mTORC1–tyrosinase axis across cells, zebrafish, and a 3D skin model, while an observational validation study confirms accurate intraoperative radiotherapy dosimetry with potential to improve cosmetic outcomes i
Summary
Three studies advance cosmetic and dermatologic science from bench to bedside. A mechanistic paper shows that juglone and plumbagin irreversibly inhibit PTP1B in keratinocytes, enhancing EGFR phosphorylation. A plant-derived extract (Saxifraga stolonifera) suppresses melanogenesis via the mTORC1–tyrosinase axis across cells, zebrafish, and a 3D skin model, while an observational validation study confirms accurate intraoperative radiotherapy dosimetry with potential to improve cosmetic outcomes in breast-conserving therapy.
Research Themes
- Mechanistic effects of cosmetic actives on skin signaling (PTP1B–EGFR)
- Natural skin-whitening agents and melanogenesis pathways (mTORC1–TYR axis)
- Quality assurance in intraoperative radiotherapy with cosmetic outcome implications
Selected Articles
1. Molecular and cellular effects of hydroxy-1,4 naphthoquinones used in dermatological and cosmetic applications on human protein tyrosine phosphatase PTP1B in human keratinocytes.
Juglone and plumbagin, but not lawsone, covalently and irreversibly inhibit PTP1B in keratinocytes by modifying catalytic Cys215, reducing phosphatase activity by up to 75%. This inhibition is associated with an approximately 3-fold increase in EGFR phosphorylation, revealing a mechanistic link by which cosmetic-relevant quinones modulate skin signaling.
Impact: Identifies PTP1B as a covalent target of widely used hydroxy-1,4-naphthoquinones and maps downstream EGFR signaling effects, informing both safety and therapeutic exploration for dermatologic/cosmetic use.
Clinical Implications: Suggests cautious formulation and dosing of juglone/plumbagin-containing products and positions PTP1B–EGFR signaling as a potential target in skin repair; in vivo safety and efficacy studies are needed before clinical translation.
Key Findings
- Juglone and plumbagin irreversibly inhibit PTP1B activity by up to 75% via modification of catalytic Cys215.
- EGFR phosphorylation increased on average 3-fold following exposure to these quinones.
- Lawsone did not inhibit PTP1B under the tested conditions.
- Effects were demonstrated in vitro and in human keratinocyte cell lines.
Methodological Strengths
- Mechanistic enzyme inhibition with residue-level specificity (Cys215) and irreversibility.
- Use of human keratinocyte models with downstream signaling readouts (EGFR phosphorylation).
Limitations
- Evidence is limited to in vitro and cell-based systems without in vivo validation.
- Dose–exposure relevance to consumer or therapeutic use is not established.
Future Directions: Test in organotypic and in vivo skin models to quantify functional outcomes (e.g., wound healing, barrier function) and define safe exposure ranges for cosmetic/therapeutic applications.
The hydroxy-1,4-naphthoquinones-lawsone, juglone, and plumbagin-widely used in dermatological and cosmetic applications, exhibit a broad spectrum of biological activities, including notable cytotoxic effects. Of the various cellular processes these quinones influence, signaling pathways hold utmost significance. This study elucidates the impact of lawsone, juglone, and plumbagin on a key tyrosine phosphatase, PTP1B, in vitro or within keratinocyte cell lines. Additionally, we assessed the phosphorylation status of EGFR and its subsequent consequences on cell migration. Our results reveal that juglone and plumbagin, but not lawsone, irreversibly inhibit PTP1B enzyme activity by up to 75% through modification of its catalytic cysteine 215 residue. These quinones also lead to an average of 3-fold increase in EGFR phosphorylation. These findings offer new insights into the molecular mechanisms through which hydroxy-1,4-naphthoquinones of dermatological or cosmetic interest modulate critical signaling pathways. SIGNIFICANCE STATEMENT: Hydroxy-1,4-naphthoquinones such as lawsone, juglone, and plumbagin are widely used in dermatological applications, yet their precise molecular and cellular effects remain underexplored. This study reveals that juglone and plumbagin irreversibly inhibit the phosphatase PTP1B by targeting its catalytic cysteine, leading to enhanced EGFR phosphorylation. These findings provide critical insights into how these compounds modulate key signaling pathways, advancing our understanding of their potential therapeutic applications in skin repair and diseases involving dysregulated cell signaling.
2. Component Analysis of Saxifraga stolonifera Extract and Its Mechanism of Melanin Inhibition.
Saxifraga stolonifera ethanol extract (SSE) shows antioxidant and tyrosinase-inhibitory activity and reduces melanogenesis across B16F10 cells, zebrafish embryos, and a 3D pigmented skin model. Mechanistically, SSE downregulates tyrosinase via the mTORC1–TYR axis, with docking suggesting mTOR binding, supporting its potential as a natural skin-whitening ingredient.
Impact: Integrates phytochemical profiling, multi-model biological validation, and pathway-level mechanism (mTORC1–TYR), moving a traditional herb toward evidence-based cosmetic development.
Clinical Implications: Supports further standardization and safety testing of SSE-derived actives for incorporation into cosmetic formulations aimed at hyperpigmentation control.
Key Findings
- HPLC–Q-TOF-MS/MS identified key constituents of the Saxifraga stolonifera ethanol extract.
- SSE exhibited antioxidant and tyrosinase-inhibitory activities in vitro.
- Anti-melanogenic effects were validated in B16F10 cells, zebrafish embryos, and a 3D reconstructed pigmented skin model.
- Mechanistic data indicate melanogenesis suppression via the mTORC1–TYR axis with downregulation of TYR mRNA/protein.
- Molecular docking suggested binding affinity of SSE components to the mTOR domain.
Methodological Strengths
- Triangulation across three biological models including a 3D human-relevant skin model.
- Mechanistic interrogation at pathway (mTORC1–TYR) and gene/protein expression levels.
Limitations
- No human clinical data; translational relevance of extract concentrations remains to be defined.
- Complex extract composition may introduce batch-to-batch variability.
Future Directions: Isolate and standardize active constituents, perform dermal pharmacokinetics/toxicology, and conduct early-phase human studies for efficacy and tolerability in hyperpigmentation.
Emerging focus on cosmetic safety has propelled exploration of plant-derived whitening agents. Saxifraga stolonifera, a traditional Chinese herb, was investigated for its whitening potential through its ethanol extract (S. stolonifera extract [SSE]). The main components were determined by high performance liquid chromatography (HPLC)-Q-TOF-MS/MS. In vitro analyses, antioxidant activity and tyrosinase (TYR) inhibition of SSE were revealed. Anti-melanogenic efficacy was systematically validated using three models: B16F10 cells, zebrafish embryos, and 3D reconstructed pigmented skin model. Mechanistic studies demonstrated SSE modulates melanogenesis by targeting the mTOR complex 1 (mTORC1)-TYR axis, downregulating TYR expression at mRNA/protein levels. Molecular docking revealed the binding affinities of SSE with mTOR domain, similar to arbutin's mechanism. Consequently, these findings suggest that SSE may function as a promising natural ingredient for cosmetic formulations, offering potent skin-whitening properties through melanogenesis inhibition.
3. Observational validation study of dosimetry using radiographic films in breast cancer intraoperative radiotherapy.
In 38 IORT cases, GAFchromic EBT-3 film dosimetry showed a mean delivered dose of 20.37 Gy (1.2% from planned 20 Gy) and low doses at surrounding tissues, corroborated by Monte Carlo simulations (<3% error). The validated film-based method provides independent verification to optimize dose accuracy and potentially improve safety, local control, and cosmetic outcomes in breast-conserving therapy.
Impact: Establishes a practical, independently verifiable dosimetry approach for IORT that aligns with Monte Carlo benchmarks, directly addressing treatment accuracy and downstream cosmetic outcomes.
Clinical Implications: Supports routine integration of GAFchromic film dosimetry as QA in IORT to ensure accurate dose delivery and minimize normal tissue exposure, potentially improving cosmesis and local control.
Key Findings
- Mean measured IORT dose was 20.37 ± 0.67 Gy, a 1.2% discrepancy from the planned 20 Gy.
- Surrounding tissue doses were low: 1.36 ± 0.92 Gy at the excision wound and 1.08 ± 1.18 Gy at the breast edge.
- Monte Carlo simulations confirmed consistency with manufacturer data with <3% error.
- Film-based dosimetry was feasible for both in vivo and in vitro verification.
Methodological Strengths
- Prospective-grade dosimetric validation embedded in real-world clinical workflow with 38 patients.
- Cross-validation against Monte Carlo simulations enhances credibility of dose accuracy.
Limitations
- Observational design without randomized comparison or long-term clinical outcomes.
- Single-region experience; generalizability to other IORT systems and settings is uncertain.
Future Directions: Multicenter implementation studies linking dosimetric accuracy to toxicity, cosmesis, and local control; exploration of broader radiotherapy contexts.
BACKGROUND AND PURPOSE: Intraoperative radiotherapy (IORT) for breast cancer offers a promising alternative to conventional external beam radiotherapy by delivering high-dose radiation directly to the tumor bed during surgery. However, accurate dosimetry is critical to ensure the safety and efficacy of this procedure. This study aimed to develop and validate a reliable dosimetry using GAFchromic EBT-3 films for precise in vivo and in vitro dosimetry during IORT. The primary objective was to verify the accuracy of absorbed delivered doses during IORT using GAFchromic EBT-3 films, in comparison with that of Monte Carlo simulations. METHODS: This observational study included 38 patients with breast cancer who underwent IORT at Kaohsiung Municipal Ta-Tung Hospital and Kaohsiung Medical University Chung-Ho Memorial Hospital in Taiwan. Patients were selected based on predefined inclusion criteria. Using GAFchromic EBT-3 films during IORT, absorbed doses, including the applicator surface, excision wound, and surrounding breast tissue, were measured at various critical points. Monte Carlo simulations were conducted to validate the accuracy of these manufacturer-provided data. RESULTS: The mean measured dose was 20.37 ± 0.67 Gy, which had a 1.2 % discrepancy from the planned dose of 20 Gy. Dose measurements at other surrounding tissues indicated effective protection, with mean doses of 1.36 ± 0.92 Gy on the excision wound and 1.08 ± 1.18 Gy on the surrounding breast edge. Monte Carlo simulations confirmed a high level of consistency with the manufacturer's data, with an error margin of <3 %. CONCLUSIONS: The use of GAFchromic EBT-3 films for dosimetry during IORT was feasible and reliable and provided an independent verification method to ensure accurate dose delivery. This study demonstrates that accurate dosimetric validation supports the clinical optimization of intraoperative radiotherapy (IORT), enabling precise dose delivery while reducing exposure to surrounding healthy tissues. These findings may contribute to enhanced treatment safety, improved local control, and favorable cosmetic outcomes in breast-conserving therapy. Further research is warranted to refine this technique and explore its applicability in other radiotherapy contexts.